GENSIGHT BIOLOGICS financials
GENSIGHT BIOLOGICS
549300NK4AB8OUEX1F54 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €1.5M | €1.3M |
| Other income | €1.1M | €1.7M |
| Operating expenses | €18.4M | €32.7M |
| Operating profit (EBIT) | -€15.8M | -€29.7M |
| Net finance income / (cost) | €1.8M | €3.5M |
| Income tax expense | €21.0K | €0 |
| Profit for the year | -€14.0M | -€26.2M |
| Total comprehensive income | -€14.2M | -€26.1M |
| Per share | ||
| Basic EPS | €-0.15 | €-0.54 |
| Diluted EPS | €-0.15 | €-0.54 |
| Free cash flow / share | €-0.14 | €-0.51 |
| Cash flow statement | ||
| Net cash from operating activities | -€12.9M | -€24.7M |
| Net cash from investing activities | €17.0K | €209.0K |
| Purchase of PP&E (capex) | €1.0K | €10.0K |
| Purchase of intangibles | €0 | €0 |
| Net cash from financing activities | €13.5M | €15.9M |
| Proceeds from borrowings | €0 | €14.2M |
| Repayments of borrowings | €2.2M | €0 |
| Lease liability payments | €742.0K | €792.0K |
| Net change in cash | €623.0K | -€8.6M |
| Balance sheet | ||
| Total assets | €10.8M | €9.1M |
| Non-current assets | €5.4M | €2.6M |
| Current assets | €5.3M | €6.5M |
| Trade & other receivables | €1.0K | €1.0K |
| Cash & equivalents | €2.5M | €2.1M |
| Total equity | -€26.9M | -€30.7M |
| Non-current liabilities | €15.1M | €14.5M |
| Lease liabilities (non-current) | €514.0K | €1.0M |
| Current liabilities | €22.6M | €25.3M |
| Current portion of long-term borrowings | €6.3M | €7.5M |
| Lease liabilities (current) | €585.0K | €775.0K |
| Derived metrics | ||
| Free cash flow | -€12.9M | -€24.7M |
| Operating margin | -1054.2% | -2343.8% |
| Net margin | -933.4% | -2069.5% |
| Return on equity | 52.0% | 85.4% |
| Cash conversion ratio | 0.92× | 0.94× |
| Capex coverage | -12937.00× | -2466.30× |
| Other reported items | ||
| Adjustments For Decrease Increase In Other Operating Receivables | €2.0M | €7.9M |
| Adjustments For Decrease Increase In Trade Account Receivable | €0 | -€1.0K |
| Adjustments For Depreciation and Amortisation Expense | €1.1M | €2.2M |
| Adjustments For Finance Income Cost | €1.7M | €3.7M |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | €22.0K | €25.0K |
| Adjustments For Increase Decrease In Other Liabilities | -€1.3M | -€3.2M |
| Adjustments For Increase Decrease In Trade Account Payable | €155.0K | -€2.2M |
| Adjustments For Sharebased Payments | €784.0K | €587.0K |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€13.8M | -€27.1M |
| Current Bonds Issued and Current Portion of Noncurrent Bonds Issued | €7.0M | €9.1M |
| Current Derivative Financial Liabilities | €0 | €0 |
| Current Provisions | €0 | €0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€293.0K | €119.0K |
| Equity and Liabilities | €10.8M | €9.1M |
| General and Administrative Expense | €5.4M | €5.4M |
| Increase Decrease In Working Capital | -€873.0K | -€2.5M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Conversion of Convertible Instruments | €3.2M | €60.0K |
| Increase Decrease Through Sharebased Payment Transactions | €784.0K | €587.0K |
| Increase Decrease Through Transfers and Other Changes Equity | €41.0K | — |
| Intangible Assets Other Than Goodwill | €57.0K | €75.0K |
| Interest Paid Classified As Financing Activities | €278.0K | €368.0K |
| Issue of Equity | €15.8M | €10.8M |
| Issued Capital | €3.1M | €1.6M |
| Noncurrent Derivative Financial Liabilities | €4.0M | €559.0K |
| Noncurrent Government Grants | €4.7M | €6.6M |
| Noncurrent Portion of Noncurrent Bonds Issued | €0 | €0 |
| Noncurrent Portion of Noncurrent Loans Received | €0 | €0 |
| Noncurrent Provisions For Employee Benefits | €1.2M | €1.3M |
| Number of Shares Outstanding | 124.8M | 65309.1M |
| Other Adjustments For Noncash Items | €0 | €0 |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€184.0K | €103.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €14.0K | €6.0K |
| Other Noncurrent Financial Assets | €4.4M | €502.0K |
| Proceeds From Exercise of Warrants | €2.7M | €60.0K |
| Proceeds From Issuing Shares | €14.0M | €4.0M |
| Purchase of Treasury Shares | €27.0K | €99.0K |
| Repayments of Bonds Notes and Debentures | — | €1.1M |
| Research and Development Expense | €12.4M | €19.4M |
| Reserve of Exchange Differences On Translation | -€152.0K | €33.0K |
| Retained Earnings Profit Loss For Reporting Period | -€14.0M | -€26.2M |
| Revenue and Operating Income | €2.6M | €3.0M |
| Sales and Marketing Expense | €685.0K | €7.9M |
| Share Issue Related Cost | €1.8M | €703.0K |
| Share Premium | €206.6M | €190.9M |
| Trade and Other Current Payables To Trade Suppliers | €6.4M | €5.6M |
Every line item above is a fact tagged in GENSIGHT BIOLOGICS's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.